Results 91 to 100 of about 7,402 (202)

A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications [PDF]

, 2016
Background: Efavirenz is part of the first-line treatment for HIV patients including South Africa with approximately 50% experiencing neuropsychiatric side effects.
Gaida, Razia, Godman, Brian, Grobler, Christoffel, Kotze, Theunis, Truter, Ilse   +4 more
core   +1 more source

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

AIDS Research and Therapy, 2019
Background Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting. Methods Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals)
Lucia Taramasso, Elena Ricci, Antonio Cascio, Laura Valsecchi, Barbara Menzaghi, Nicola Squillace, Paolo Maggi, Giuseppe Vittorio De Socio, Chiara Dentone, Giordano Madeddu, Giovanni F. Pellicanò, Leonardo Calza, Goffredo Angioni, Paolo Bonfanti, Antonio Di Biagio, CISAI Study Group   +15 more
doaj   +1 more source

Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals. [PDF]

, 2017
Our study aimed to investigate the short-term effect of combination antiretroviral therapy (cART) on cognitive performance and functional and structural connectivity and their relationship to plasma levels of antiretroviral (ARV) drugs.
Arduino, Roberto C, Luque, Amneris, Ma, Qing, Mapstone, Mark, Miller, Eric, Qiu, Xing, Schifitto, Giovanni, Tivarus, Madalina, Wang, Lu, Weber, Miriam, Zhong, Jianhui, Zhuang, Yuchuan   +11 more
core   +1 more source

Estimating HIV Medication Adherence and Persistence: Two Instruments for Clinical and Research Use [PDF]

, 2018
Antiretroviral therapy (ART) requires lifelong daily oral therapy. While patient characteristics associated with suboptimal ART adherence and persistence have been described in cohorts of HIV-infected persons, these factors are poor predictors of ...
Allmon, Andrew G., Hudgens, Michael G., Kirby, Christine, Magnus, Brooke E., Mollan, Katie R., Panter, A. T., Wohl, David A.   +6 more
core   +3 more sources

The role of drug transporters in the kidney: lessons from tenofovir [PDF]

, 2014
Tenofovir disoproxil fumarate, the prodrug of nucleotide reverse transcriptase inhibitor tenofovir, shows high efficacy and relatively low toxicity in HIV patients.
Moss, DM, Neary, M, Owen, A
core   +2 more sources

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials

HIV Research & Clinical Practice, 2019
Background: The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naive and ART-experienced Asian ...
Yeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, Amanda Clarke, Khuanchai Supparatpinyo, Anchalee Avihingsanon, Winai Ratanasuwan, Sasisopin Kiertiburanakul, Kiat Ruxrungtham, SangYoun Yang, Susan Guo, YaPei Liu, Moupali Das, Do Tran, Damian McColl, Roberto Corales, Chris Nguyen, David Piontkowsky   +17 more
doaj   +1 more source

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary Circulation, 2019
Riociguat, a first-in-class soluble guanylate cyclase stimulator, is approved for the treatment of pulmonary arterial hypertension (PAH), a serious potential complication of human immunodeficiency virus (HIV) infection. This open-label study investigated
Edwin DeJesus, Soundos Saleh, Sue Cheng, Dorina van der Mey, Corina Becker, Reiner Frey, Sigrun Unger, Wolfgang Mueck   +7 more
doaj   +1 more source

2016 Pipeline Report HIV and TB [PDF]

, 2016
HIV and TB: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in ...
Erica Lessem, Lindsay McKenna, Mark Harrington, Mike Frick, Polly Clayden, Richard Jefferys, Simon Collins, Tim Horn   +7 more
core  

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors.

PLoS ONE, 2019
BackgroundWe aimed to describe the most frequently prescribed initial antiretroviral therapy (ART) regimens in recent years in HIV-positive persons in the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) and to investigate factors associated with ...
Belén Alejos, Inés Suárez-García, Otilia Bisbal, José Antonio Iribarren, Víctor Asensi, Miguel Górgolas, Roberto Muga, Santiago Moreno, Inma Jarrín, CoRIS cohort   +9 more
doaj   +1 more source

Choice of antiretroviral drugs for continued treatment scale‐up in a public health approach: what more do we need to know?

Journal of the International AIDS Society, 2016
Introduction There have been several important developments in antiretroviral treatment in the past two years. Randomized clinical trials have been conducted to evaluate a lower dose of efavirenz (400 mg once daily).
Marco Vitoria, Andrew M Hill, Nathan P Ford, Meg Doherty, Saye H Khoo, Anton L Pozniak   +5 more
doaj   +1 more source